Health● Low35m ago · Nov 10, 2026, 8:02 PM
Protalix sees $3.2B Fabry market by 2031 while targeting PRX-115 Phase II top-line results in H2 next year
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Protalix projects a substantial market for Fabry disease by 2031 and anticipates top-line results for its PRX-115 Phase II trial next year. This indicates developments in the pharmaceutical sector for a specific disease.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Health
Not flagged as developing.
More in Health
Health50m agoEmbrace HIV testing as routine healthcare-Lagos govt urges residentsVanguard NigeriaHealth2h agoNew appeals trial for Schmidheiny in Eternit asbestos deaths caseANSA [en]Health2h agoHemab expects cash to fund operations into 2029 while advancing ~75-patient SOLARA Phase IIISeeking Alpha TechHealth2h agoFG provides 80,906 free caesarean sections, reports 22% drop in obstetric emergency deathsPremium Times